Cobaltoceniumselenolate Gold(I) Complexes: Synthesis, Spectroscopic, Structural and Anticancer Properties

Cobaltoceniumselenolate is an unusual, highly air‐sensitive, mesoionic compound containing a very soft anionic selenium donor atom. Here we explore its coordination chemistry with Au(I) metal centers and show that its hetero‐ and homoleptic gold complexes are highly colored, air‐stable compounds, wh...

Full description

Saved in:
Bibliographic Details
Published in:European journal of inorganic chemistry 2021-07, Vol.2021 (27), p.2784-2786
Main Authors: Menia, Daniel, Kopacka, Holger, Wurst, Klaus, Müller, Thomas, Lippmann, Petra, Ott, Ingo, Bildstein, Benno
Format: Article
Language:English
Subjects:
Anticancer properties
Cancer
Cobalt
Communication
Communications
Coordination compounds
Cytotoxicity
Gold
Inorganic chemistry
NMR
Nuclear magnetic resonance
Sandwich complexes
Selenium
Single crystals
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cobaltoceniumselenolate is an unusual, highly air‐sensitive, mesoionic compound containing a very soft anionic selenium donor atom. Here we explore its coordination chemistry with Au(I) metal centers and show that its hetero‐ and homoleptic gold complexes are highly colored, air‐stable compounds, which were characterized by 1H/13C/31P/77Se NMR, IR, UV‐Vis, HR‐MS and single crystal XRD. Cytotoxicity of these polar, water‐soluble complexes was studied against various standard cancer cell lines (A549MDA‐MB‐231, HT‐29) revealing good anticancer activity of all three complexes. Air‐stable homo‐ and heteroleptic gold(I) complexes containing the unusual zwitterionic cobaltoceniumselenolate ligand were synthesized and fully characterized. First preliminary biological test against three standard human cancer cell lines showed good cytotoxicity properties, indicating that cobaltocenium selenolate is a promising ligand for future developments of redox‐active organometallic metallo‐drugs for anticancer therapy.
ISSN:1434-1948
1099-0682
DOI:10.1002/ejic.202100379